Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2025 Feb 18;192(3):402-409.
doi: 10.1093/bjd/ljae406.

Deucravacitinib, an oral selective allosteric tyrosine kinase 2 inhibitor, in patients from China mainland, Taiwan and South Korea with moderate-to-severe plaque psoriasis: a phase III randomized clinical trial

Jianzhong Zhang  1 , Yangfeng Ding  2 , Ping Wang  3 , Linfeng Li  4 , Weili Pan  5 , Yan Lu  6 , Hao Cheng  7 , Xian Jiang  8 , Ji-Chen Ho  9 , Shuping Guo  10 , Leona Liu  11 , Arkendu Chatterjee  11 , Renata M Kisa  11 , Subhashis Banerjee  11
Affiliations
Clinical Trial

Deucravacitinib, an oral selective allosteric tyrosine kinase 2 inhibitor, in patients from China mainland, Taiwan and South Korea with moderate-to-severe plaque psoriasis: a phase III randomized clinical trial

Jianzhong Zhang et al. Br J Dermatol. .

Abstract

Background: Deucravacitinib, an oral selective allosteric tyrosine kinase 2 inhibitor, is approved in the USA, the European Union, Japan, South Korea, China and other countries for the treatment of moderate-to-severe plaque psoriasis.

Objectives: To evaluate the efficacy and safety of deucravacitinib in Asian patients with moderate-to-severe plaque psoriasis.

Methods: In the 52-week blinded phase III POETYK PSO-3 trial (NCT04167462), patients were randomized 1 : 2 to placebo (n = 74) or deucravacitinib 6 mg once daily (n = 146) for 16 weeks followed by deucravacitinib alone. Co-primary endpoints were the achievement of a ≥75% reduction from baseline in Psoriasis Area and Severity Index (PASI 75) and static Physician Global Assessment score of 0 (clear) or 1 (almost clear; sPGA 0/1) at week 16. Efficacy and safety were evaluated throughout.

Results: At week 16, significantly higher proportions of patients receiving deucravacitinib compared with placebo achieved PASI 75 (68.8% vs. 8.1%; P < 0.001) and sPGA 0/1 (55.6% vs. 6.8%; P < 0.001). Response rates with deucravacitinib were maintained through week 52. Common adverse events (AEs) included upper respiratory tract infection and nasopharyngitis. Serious AE and discontinuation rates were low.

Conclusions: Deucravacitinib was efficacious and well tolerated in Asian patients with moderate-to-severe plaque psoriasis.

Plain language summary

Plaque psoriasis is a skin disease that causes thick and scaly patches called ‘plaques’ on the body. Deucravacitinib (doo-krav-a-sit-in-ib) is a type of medicine for psoriasis. It can stop plaques from forming or improve existing ones. Two clinical trials have shown that deucravacitinib improves psoriasis symptoms within 4 months. We wanted to find out if deucravacitinib works and is safe in Asian people with moderate-to-severe plaque psoriasis. The trial included 220 people from China mainland, Taiwan and South Korea. Some people took deucravacitinib every day for a year. Other people took a placebo (a pill with no active medicine) for the first 4 months and then switched to deucravacitinib. After 4 months, most people who took deucravacitinib saw an improvement in their psoriasis symptoms. They also had skin that was clear or almost clear of psoriasis. People with psoriasis on their scalp also had improved symptoms after taking deucravacitinib. Deucravacitinib continued to work over 1 year. Most people who took part had no serious medical problems during the study. Five patients stopped taking deucravacitinib because of side effects. Five patients developed mild cases of shingles but did not stop taking deucravacitinib. The results suggest that deucravacitinib helps to improve the symptoms of psoriasis in Asian people with psoriasis. The side effects were generally mild.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: J.Z. has served as a consultant for and received honoraria from Akeso Biopharma Co Ltd, Beijing Wenfeng Tianji Pharma Ltd, GSK (China) Investment Co Ltd, Keymed Biosciences (Chendu) Ltd, Kintor Pharmaceutical Ltd, LEO Pharma (Shanghai) Co Ltd, Lilly China, Novartis Pharmaceuticals (China), Pfizer Investment Co Ltd, Reistone Biopharma Co Ltd, Sanofi China and Xian Janssen Pharmaceutical Co Ltd. L. Liu and R.M.K., are employees of and stockholders in Bristol Myers Squibb. A.C. and S.B. were employees of Bristol Myers Squibb at the time of study conduct and are stockholders in Bristol Myers Squibb. Y.D., P.W., L. Li, W.P., Y.L., H.C., X.J., J.-C.H. and S.G. declare no conflicts of interest.

Publication types

Grants and funding